Elixir Medical's DynamX Bioadaptor restores natural artery function, reducing the risk of future cardiac events.

First Live Case Transmission in the US of the CE Mark-approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System Sunnyvale, CA—Elixir Medical Corporation, a developer of ...

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a ...

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark ...

MILPITAS, Calif. & PARIS--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced at EuroPCR ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...

MILPITAS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, announced results from the MY-IVL Study at the Transcatheter ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

MILPITAS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced new landmark clinical results for its ...

(MENAFN- GlobeNewsWire - Nasdaq) LithiXTM HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...